Mylan has biosimilar aspirations for Botox
Mylan is teaming up with California-based biotechnology firm Revance Therapeutics to develop and commercialise a biosimilar of Allergan’s world-renowned Botox (onabotulinumtoxinA) injection, as part of Mylan’s long-term strategy to bring to market complex products and biosimilars, as well as to gain traction in the growing global market for neuromodulators.
You may also be interested in...
Viatris remains hopeful of obtaining FDA approval for its proposed biosimilar to Botox in partnership with Revance Therapeutics in 2026, after the latter’s manufacturing problems for another drug candidate stymied development of the rival to the world-renowned cosmetic brand.
Mylan is preparing to launch a trastuzumab biosimilar in the US, while progress of developing bevacizumab and aflibercept biosimilars continues. Insulin aspart and glargine are also in Mylan’s pipeline.
Revance has amended its agreement with Mylan to collaborate on a rival version of Botox to give Mylan more time to decide on whether it wants to continue developing the biosimilar. In turn, Mylan has agreed to pay $5m to Revance for the extended deadline.